Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 36%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Icon has demonstrated strong growth potential with a notable 11% sequential increase in gross business awards, driven by several significant wins with biotech customers and the expansion of partnerships with large pharmaceutical companies. The company has also exceeded its financial targets following the PRA acquisition and possesses a favorable client mix, positioning it well against uncertainties in funding environments. Furthermore, Icon is poised to accelerate clinical trial research in a rapidly growing contract research organization (CRO) market, supported by an improving win rate within its operational segment.

Bears say

The financial outlook for Icon indicates a decline in EBITDA margin expectations, shifting from previous estimates of approximately 20% down to the high-19% range for both the current year and 2025. This marginal decrease reflects ongoing challenges primarily related to gross margin dynamics and highlights concerns regarding the company's capacity to meet revenue synergies from its PRA transaction. Additionally, external factors such as potential decreases in clinical trial activity, biotech funding uncertainties, and inflationary pressures further contribute to a negative outlook for the company's performance.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 36% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $210.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $210.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.